目的 联合使用一种新的表达Epstein Barr病毒（EBV）裂解性复制极早期基因Rta的杆状病毒载体及抗病毒药物更昔洛韦，试验其对激活鼻咽癌细胞中潜伏性EBV的复制和杀伤肿瘤细胞的作用。方法 用携带EBV的复制起点OriP和CMV启动子表达Rta基因的重组杆状病毒处理EBV潜伏感染的鼻咽癌细胞Hone1-EBV，和由该细胞系建立的裸鼠肿瘤模型，同时联合使用更昔洛韦，研究细胞和肿瘤生长的情况。结果 重组杆状病毒和更昔洛韦联合处理肿瘤细胞后，细胞生长活性仅为对照的51%，裸鼠活体实验中肿瘤生长也受到明显的抑制，10 d后瘤体积仅为对照的20%，瘤重仅为对照的30%。组织化学分析证实大量肿瘤细胞坏死。结论 杆状病毒载体与更昔洛韦联合可以用于EBV相关的鼻咽癌的治疗。

Objective To test a novel baculovirus expressing Epstein-Barr virus (EBV) lytic replication immediate early gene Rta, in combination with antiviral chemical ganciclovir, for the activation of latent EBV in nasopharyngeal carcinoma (NPC) cells, and the killing of tumor cells. Methods A baculovirus vector with EBV replication origin OriP, and the Rta expression cassette led by CMV promoter, was used to treat EBV-latently infected NPC cell line Hone1-EBV, as well as nude mice tumor model established from the cell line, in combination with ganciclovir. The effect on the growth of cell and tumor was studied. Results When treated with recombinant baculovirus in combinantion with ganciclovir, the growth of EBV-positive cells was significantly reduced to only 51% of the control. In the nude mice experiments, tumor growth was also greatly reduced. At 10th day after the first injection, the average volume and weight of the treated group was only about 20% and 30% of that of the control group, respectively. Histological analysis indicated there was significant cell necrosis in the baculovirus-ganciclovir-treated tumor tissue. Conclusion Co-application of RTA-expressing baculovirus vector and gancyclovir may be useful for the therapy of EBV associated NPC.